Search results for "block"

showing 10 items of 1177 documents

TNF-α blockade may lead to improvement of vascular function in psoriasis patients.

2021

Psoriasis is one of the most common chronic inflammatory skin diseases and at the same time a risk factor for cardiovascular disease. Interleukin-17A (IL-17A)-mediated inflammation in psoriasis may lead to vascular dysfunction. This study aimed at investigating whether anti-inflammatory treatment by tumor necrosis factor (TNF)-α blockade alters vascular function in psoriasis patients. A total of 11 patients with psoriasis who underwent treatment with either adalimumab (n = 8) or etanercept (n = 3), 10 healthy control individuals and 14 patients with coronary artery disease (CAD) were included in this study. Treatment response was assessed using the Psoriasis Area and Severity Index (PASI) s…

medicine.medical_specialtyDermatologyBiochemistryGastroenterologyEtanerceptCoronary artery diseasePsoriasis Area and Severity IndexInternal medicinePsoriasismedicineAdalimumabHumansPsoriasisRisk factorMolecular Biologybusiness.industryTumor Necrosis Factor-alphamedicine.diseaseBlockadeVasodilationVasoconstrictionChronic DiseaseTumor necrosis factor alphaTumor Necrosis Factor InhibitorsEndothelium Vascularbusinessmedicine.drugExperimental dermatologyREFERENCES
researchProduct

Role of antiangiogenic VEGF-A165b in angiogenesis and systolic function after reperfused myocardial infarction

2021

Abstract Introduction and objectives Angiogenesis helps to reestablish microcirculation after myocardial infarction (MI). In this study, we aimed to further understand the role of the antiangiogenic isoform vascular endothelial growth factor (VEGF)-A165b after MI and to explore its potential as a coadjuvant therapy to coronary reperfusion. Methods Two mice MI models were formed: a) permanent coronary ligation (nonreperfused MI); b) transient 45-minute coronary occlusion followed by reperfusion (reperfused MI); in both models, animals underwent echocardiography before euthanasia at day 21 after MI induction. We determined serum and myocardial VEGF-A165b levels. In both experimental MI models…

medicine.medical_specialtyEjection fractionbusiness.industryAngiogenesisGeneral Medicine030204 cardiovascular system & hematologymedicine.diseaseMicrocirculationBlockadeVascular endothelial growth factor03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistryCoronary occlusionHeart failureInternal medicinemedicineCardiologyMyocardial infarctionbusinessRevista Española de Cardiología (English Edition)
researchProduct

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis

2015

Outcomes from 5 years of treatment with agalsidase alfa enzyme replacement therapy (ERT) for Fabry disease in patients enrolled in the Fabry Outcome Survey (FOS) were compared with published findings for untreated patients with Fabry disease. Data were extracted from FOS, a Shire-sponsored database, for comparison with data from three published studies. Outcomes evaluated were the annualized rate of change in estimated glomerular filtration rate (eGFR) and left ventricular mass indexed to height (LVMI) as well as time to and ages at a composite morbidity endpoint and at death. FOS data were extracted for 740 treated patients who were followed for a median of ~ 5 years. Compared with no trea…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismUrologyCardiomyopathyRenal functionSE Standard errorLeft ventricular hypertrophyBiochemistryLVH Left ventricular hypertrophyLong-term effectivenessEndocrinologyGeneticsMedicineMDRD Modification of Diet in Renal Diseaselcsh:QH301-705.5Molecular BiologyAgalsidase alfaeGFR Estimated glomerular filtration rateFabry diseaselcsh:R5-920CI Confidence intervalbusiness.industryEnzyme replacement therapymedicine.diseaseEgfr Estimated glomerular filtration rateFabry diseaseSurgeryARB Angiotensin receptor blockerSEM Standard error of the meanStandard errorlcsh:Biology (General)SI:TherapyEnzyme replacement therapyCohortFOS Fabry Outcome SurveyLVMI Left ventricular mass indexed to heightlcsh:Medicine (General)businessACEI Angiotensin-converting enzyme inhibitorAgalsidase alfaERT Enzyme replacement therapyMolecular Genetics and Metabolism Reports
researchProduct

Influence of different CyA formulations and calcium channel blocker phenyhidine regimens on intracellular (erythrocyte) calcium levels after kidney t…

1997

medicine.medical_specialtyErythrocytesmedicine.drug_classPrednisolonechemistry.chemical_elementAdministration OralCalcium channel blockerCalciumInternal medicineAzathioprinemedicineHumansDrug InteractionsKidney transplantationDosage FormsTransplantationKidneybusiness.industryCiclosporinmedicine.diseaseCalcium Channel BlockersKidney TransplantationTransplantationEndocrinologymedicine.anatomical_structurechemistryToxicityCyclosporineSurgeryCalciumEmulsionsbusinessIntracellularImmunosuppressive Agentsmedicine.drugTransplantation proceedings
researchProduct

Improvement of asymmetric thyroid eye disease with teprotumumab

2021

PurposeTeprotumumab, a specific blocking antibody to the insulin like growth factor 1 receptor, significantly reduced proptosis in patients with thyroid eye disease (TED) in recent clinical trials. Given its specificity, we expect it to demonstrate greater efficacy on the worse affected orbit, in patients with asymmetric TED. Herein, we investigate the differential impact of teprotumumab on the orbits of such patients.MethodsIn this pooled analysis of patients who were enrolled in the recent phase 2 (NCT01868997) and phase 3 (NCT03298867) trials, all patients with asymmetric TED (difference in exophthalmometry of ≥3 mm) were screened for eligibility. The primary outcomes of the trials, prop…

medicine.medical_specialtyEye disease030209 endocrinology & metabolismAntibodies Monoclonal HumanizedPlacebo03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineInternal medicineBlocking antibodyDiplopiamedicineExophthalmosHumansDifferential impactDiplopiabusiness.industryThyroidmedicine.diseaseeye diseasesSensory SystemsGraves OphthalmopathyClinical trialOphthalmologyPooled analysismedicine.anatomical_structure030221 ophthalmology & optometrymedicine.symptombusinessBritish Journal of Ophthalmology
researchProduct

Pharmacological Therapy in Children with Atrial Fibrillation and Atrial Flutter

2008

Heart rhythm disorders in children are not different, on electrocardiographic trace, from heart rhythm disorders in adults with the exception of incidence which is different according to the age. Paticularly, atrial flutter (FlA) and fibrillation (FA) are very uncommon arrhythmias in the general pediatric population. Generally atrial fibrillation and atrial flutter, in our experience, is a temporary heart rhythm disturbance connected to specifical and resovable reasons with the exception of Fontains surgical correction of congenital heart diseases or cardiopathies with dilatation of both atria. Presenting symptoms, symptom history (e.g., frequency, duration, and severity), risk assessment, …

medicine.medical_specialtyHeart diseasemedicine.medical_treatmentAdrenergic beta-AntagonistsElectric CountershockPHARMACOLOGICAL THERAPY IN CHILDREN WITH ATRIAL FIBRILLATION AND ATRIAL FLUTTER.Catheter ablationElectrocardiographyPharmacotherapyInternal medicineAtrial FibrillationDrug DiscoverymedicineHumanscardiovascular diseasesChildUltrasonographyPharmacologyFibrillationmedicine.diagnostic_testbusiness.industryIncidence (epidemiology)Cardiac Pacing ArtificialAtrial fibrillationCalcium Channel Blockersmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareAtrial fibrillation atrial flutter pharmacological therapy childrenAtrial FlutterChronic DiseaseCatheter Ablationcardiovascular systemCardiologymedicine.symptombusinessAnti-Arrhythmia AgentsElectrocardiographyAtrial flutterCurrent Pharmaceutical Design
researchProduct

The Contribution of Cell Blocks in the Diagnosis of Mediastinal Masses and Hilar Adenopathy Samples from Echobronchoscopy

2014

medicine.medical_specialtyHilar adenopathyLung Neoplasmsbusiness.industryGeneral Medicine03 medical and health sciences0302 clinical medicineText mining030228 respiratory system030220 oncology & carcinogenesisMediastinal DiseasesmedicineHumansRadiologybusinessLymphatic DiseasesCell blockArchivos de Bronconeumología (English Edition)
researchProduct

Hypoosmolar conditions reduce extracellular volume fraction and enhance epileptiform activity in the CA3 region of the immature rat hippocampus

2006

The osmolarity of the extracellular space (ECS) compartment is an important factor determining the excitability of neuronal tissue. In the adult hippocampus an important role of osmolarity and ECS diffusion parameters on the susceptibility to epileptic events is well established, but the influence of hypo- and hyperosmolar conditions on the immature hippocampus remains elusive. To investigate the influence of osmolarity on epileptiform activity, extracellular field potentials were recorded in the CA3 region of hippocampal slices of immature (postnatal days 4-7) Wistar rats. The ECS diffusion parameters were determined by the real-time tetramethylammonium (TMA+) iontophoretic method with ion…

medicine.medical_specialtyHippocampusAlpha (ethology)In Vitro TechniquesHippocampal formationHippocampusCellular and Molecular Neurosciencechemistry.chemical_compoundInternal medicinePotassium Channel BlockersmedicineExtracellularAnimalsMagnesium4-AminopyridineRats WistarNeuronsOsmoleTetramethylammoniumEpilepsyDose-Response Relationship DrugOsmotic concentrationIontophoresisOsmolar ConcentrationRatsQuaternary Ammonium CompoundsEndocrinologyAnimals NewbornHypotonic SolutionschemistryExtracellular SpaceNeuroscienceJournal of Neuroscience Research
researchProduct

Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis

2013

Interstitial lung disease (ILD) is a common extra-articular manifestation of rheumatoid arthritis (RA) and a significant cause of morbidity and mortality. Usual interstitial pneumonia and nonspecific interstitial pneumonia seem to be the most frequent patterns in RA patients with ILD, although the proportion of patients with usual interstitial pneumonia is higher than among patients with other systemic rheumatic autoimmune diseases. RA patients with ILD most frequently present with chronic symptoms of cough and dyspnea when climbing stairs or walking uphill. A physical examination may reveal inhalatory crackles and a pulmonary function test demonstrates restrictive physiology, often with re…

medicine.medical_specialtyImmunologyArthritisLung biopsyGastroenterologyPulmonary function testingArthritis RheumatoidAntibodies Monoclonal Murine-DerivedPatient Education as TopicUsual interstitial pneumoniaInternal medicinemedicineHumansImmunology and AllergyAntibodies BlockingPneumonitisLeflunomideClinical Trials as TopicTumor Necrosis Factor-alphabusiness.industryInterstitial lung diseaseIsoxazolesmedicine.diseaserespiratory tract diseasesMethotrexateAntirheumatic AgentsRheumatoid arthritisImmunologyLung Diseases InterstitialRituximabbusinessLeflunomidemedicine.drugExpert Review of Clinical Immunology
researchProduct

Gastrin: an acid-releasing, proliferative and immunomodulatory peptide?

2010

Gastrin release is affected by gastric inflammatory conditions. Antral G cells respond to inflammatory mediators by increasing gastrin secretion. Accumulating experimental evidence suggests that gastrin exerts immunomodulatory and proinflammatory effects. Gastrin could be a contributing factor to these pathologies, which may constitute a new justification for pharmacological blockade of gastrin action.

medicine.medical_specialtyInflammationdigestive systemProinflammatory cytokineGastric AcidImmunomodulationInternal medicineDrug DiscoveryGastrinsmedicineAnimalsHumansSecretionGastrin-Secreting CellsProtein PrecursorsAntrumGastrinCell ProliferationPharmacologyChemistrydigestive oral and skin physiologyGeneral MedicineBlockadeImmunomodulatory peptideEndocrinologyGastrinomaGastritisReceptors CholecystokininG cellmedicine.symptomhormones hormone substitutes and hormone antagonistsSignal TransductionMini reviews in medicinal chemistry
researchProduct